• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lumos Pharma Inc. (Amendment)

    6/2/23 11:14:55 AM ET
    $LUMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LUMO alert in real time by email
    SC 13D/A 1 formsc13da.htm FORM SC 13D/A Regulatory Counsel LLC: Form SC 13D/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934 (Amendment No. 2)

    Lumos Pharma, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    55028X109

    (CUSIP Number)


    Scott D. Pomfret, Regulatory Counsel LLC, 43 Commercial St., Provincetown MA

    (617) 680-5482
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 30, 2023

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  [ X  ].

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See 240.13d-7(b) for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13D

    CUSIP No. 55028X109

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Daniel Farb
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [  ]
    (b)  [ X  ]
    3 SEC USE ONLY

              
    4 SOURCE OF FUNDS (See Instructions)

    PF
    5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

                [   ]
    6 CITIZENSHIP OR PLACE OF ORGANIZATION

    CANADA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER

    496,891
    8 SHARED VOTING POWER

     
    9 SOLE DISPOSITIVE POWER

    496,891
    10 SHARED DISPOSITIVE POWER

     
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    496,891
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

              [   ]
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    6.08%
    14 TYPE OF REPORTING PERSON (See Instructions)

    IN
         


    Page 2

    Item 1. Security and Issuer

    (a) Name of Issuer: Lumos Pharma, Inc.

    (b) Title and Class of Securities: Common Stock

    (c) Address of Issuer's Principal Executive Offices:

    4200 Marathon Blvd., Suite 200

    Austin, Texas 78756

    Item 2. Identity and Background

    (a) Name of Person Filing: Daniel Farb ("Reporting Person")

    (b) Address of Principal Business Office or, if None, Residence: 

    38 Newbury St., 5th Fl.

    Boston MA 02116

    (c) Occupation/Employment: Investor

    (d) N/A. During the last five years, the Reporting Persons has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) N/A. During the last five years, the Reporting Persons has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and was not and is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Citizenship: Canada 

    Item 3. Source and Amount of Funds or Other Considerations

    The source of funds for the acquisition of the holdings set forth in the original Schedule 13D and this Schedule 13D/A was the Reporting Person’s personal finances in the amount of approximately $6,315,600.

    Item 4. Purpose of Transaction

    The original purpose of the transactions that occasioned this filing was an investment by the reporting person in the ordinary course of his business and with neither the purpose nor effect of changing or influencing the control of the Issuer, nor in connection with or as a participant in any transaction having such purpose or effect. Beginning February 13, 2023, however, the Reporting Person determined to initiate discussions with management and the Board of the Issuer concerning ways to create shareholder value through improved capital allocation that may address the Issuer’s current negative enterprise value. To date, such discussions have been preliminary and exploratory in nature, and haven’t risen to the level of a plan or proposal.


    Page 3

    The Reporting Person may, from time to time, acquire or dispose of additional shares of Common Stock in the open market or in privately negotiated transactions. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, and other future developments.

    Except as set forth above, as of the date of this Schedule 13D, the Reporting Persons has no other present plans which relate to or would result in:

    (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

    (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

    (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

    (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

    (e) Any material change in the present capitalization or dividend policy of the Issuer;

    (f) Any other material change in the Issuer's business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

    (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

    (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

    (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

    (j) Any action similar to any of those enumerated above.

    Notwithstanding the foregoing, the Reporting Person, at any time and from time to time, may review, reconsider and change his position and/or change his purpose and/or develop such plans and may seek to influence management or the Board of the Issuer with respect to the business and affairs of the Issuer and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.

    Item 5. Interest in Securities of the Issuer

    (a) 496,891 shares (6.08%) by the Reporting Person.

    (b) 496,891 shares (6.08%) by the reporting person (sole power).

    (c) The Reporting Person effected the following transactions (sales) in the relevant securities of the Issuer within the last sixty days in the Reporting Person's personal brokerage account:


    Page 4


    DATE SHARES PRICE/SHARE 
         

    05/25/2023

    513

    $3.6562

         

    05/25/2023

    4520

    $3.6456

         

    05/25/2023

    1100

    $3.5064

         

    05/26/2023

    3931

    $3.6836

         

    05/30/2023

    100

    $3.9000

         

    05/30/2023

    3174

    $3.8500

         

    05/30/2023

    1600

    $3.9500

         

    05/30/2023

    385

    $3.8800

         

    05/30/2023

    300

    $3.8633

         

    05/30/2023

    6460

    $3.8588

         

    05/30/2023

    2623

    $3.8077

         

    05/30/2023

    221

    $3.8000

         

    05/30/2023

    1200

    $3.7908

         

    05/30/2023

    3007

    $3.7738

         

    05/30/2023

    11671

    $3.7406

         

    05/30/2023

    2533

    $3.7206

         

    05/30/2023

    16000

    $4.1200

         

    05/30/2023

    825

    $4.1573

         

    05/30/2023

    1426

    $4.1249

         

    05/30/2023

    1200

    $4.0517

         

    05/30/2023

    5569

    $4.0807

         

    05/30/2023

    1835

    $4.0533



    Page 5


    05/30/2023

    3145

    $4.0455

         

    05/30/2023

    5513

    $4.1500

         

    05/30/2023

    2800

    $4.1661

         

    05/30/2023

    1503

    $4.1007

         

    05/30/2023

    2150

    $4.0621

         

    05/30/2023

    8547

    $4.1371

         

    05/30/2023

    17972

    $4.1414

         

    05/30/2023

    270

    $4.0537

         

    05/30/2023

    579

    $4.0077

         

    05/30/2023

    1150

    $3.9757

         

    05/30/2023

    2291

    $3.9631

         

    05/30/2023

    300

    $3.9533

         

    05/31/2023

    813

    $3.9754

         

    05/31/2023

    30

    $3.9000

         

    05/31/2023

    570

    $3.8018

         

    05/31/2023

    88

    $3.8700

         

    05/31/2023

    9843

    $3.7802

         

    05/31/2023

    1366

    $3.7500

         

    05/31/2023

    1101

    $3.7698

         

    05/31/2023

    1352

    $3.7400

         

    05/31/2023

    1862

    $3.7143

         

    05/31/2023

    600

    $3.8000

         

    05/31/2023

    150

    $3.7500

         

    05/31/2023

    1396

    $3.7012

         

    05/31/2023

    2300

    $3.6807



    Page 6


    06/01/2023

    5454

    $3.5622

         

    06/01/2023

    172

    $3.7500

         

    06/01/2023

    2937

    $3.6109

    (d) N/A

    (e) N/A

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    None.

    Item 7. Material to Be Filed as Exhibits

    None

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    June 2, 2023

     

    Dated

     

       

    /s/ Scott D. Pomfret

     

       

    Signature

     

       
    Scott Pomfret, Attorney-in-Fact for the Reporting Person*  
       

     

     

    Name/Title

     

    *Power of Attorney previously filed with IARD in connection with reporting person's Form 13H filings.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


    Get the next $LUMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUMO

    DatePrice TargetRatingAnalyst
    11/4/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    7/21/2021$34.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LUMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:39 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:27 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - LUMOS PHARMA, INC. (0001126234) (Issuer)

      12/13/24 9:32:17 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

      AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, End

      7/26/21 4:18:40 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

      AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. After a distinguished 40-year career as an accountant and financial executive, including over 15 successful years with the Company and its predecessor, Chief Financial Officer Carl Langren has announced his plans to retire effective as of July 4, 2021. Mr. Langren has served as CFO of the Company since November 2018. After his departure, Mr. Langren will continue to serve as a consultant to Lumos Pharma for a

      4/20/21 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Financials

    Live finance-specific insights

    See more
    • Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

      Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa

      8/1/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

      AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio

      7/23/24 4:05:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

      Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, today announced the outcome from its End-of-Phase 2 meeting with the FDA, provided a clinical programs update, and reported financial results for the quarter ended March 31

      5/14/24 4:15:00 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LUMO
    SEC Filings

    See more
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      11/12/24 6:27:22 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Lumos Pharma Inc. (Amendment)

      SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/9/24 7:14:19 PM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Lumos Pharma Inc.

      SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)

      2/6/24 9:57:23 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Lumos Pharma Inc.

      15-12G - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/23/24 8:00:07 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form AW filed by Lumos Pharma Inc.

      AW - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 8:10:29 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Lumos Pharma Inc.

      EFFECT - LUMOS PHARMA, INC. (0001126234) (Filer)

      12/13/24 12:15:10 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

      AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC ("DPV") today announced the successful completion of the previously announced tender offer for Lumos Pharma's shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right ("CVR") for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone even

      12/12/24 8:47:38 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action

      AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. "The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201's pulsatile

      11/21/24 9:00:00 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LUMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/4/21 6:27:17 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Lumos Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $27.00 from $34.00 previously

      7/21/21 11:37:35 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lumos Pharma upgraded by Stifel with a new price target

      Stifel upgraded Lumos Pharma from Hold to Buy and set a new price target of $24.00 from $4.00 previously

      3/11/21 8:10:40 AM ET
      $LUMO
      Biotechnology: Pharmaceutical Preparations
      Health Care